Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "User talk:Kammerhofer Sylvia/My sandbox"

From Bioblast
Line 28: Line 28:




::::* Alma Mater Studiorum – Università di Bologna - Italy
::::* Alma Mater Studiorum – Università di Bologna - IT
::::* Universite Catholique de Louvain - Belgium  
::::* Universite Catholique de Louvain - Belgium  
::::* OROBOROS INSTRUMENTS GmbH - Austria
::::* OROBOROS INSTRUMENTS GmbH - AT
::::* Justus Liebig UniversitÀt Giessen - Germany
::::* Justus Liebig UniversitÀt Giessen - GE
::::* GemeinnĂŒtzige Salzburger Landeskliniken Betriebsgesellschaft  - Austria
::::* GemeinnĂŒtzige Salzburger Landeskliniken Betriebsgesellschaft  - AT
::::* Karolinska Institutet  - Sweden  
::::* Karolinska Institutet  - Sweden  
::::* The Chancellor, Masters and Scholars of the University of Cambridge - United Kingdom
::::* The Chancellor, Masters and Scholars of the University of Cambridge - UK
::::* Association pour le dĂ©veloppement de l'enseignement et des recherches aupres des universities et des enterprises d’aquitaine - France
::::* Association pour le dĂ©veloppement de l'enseignement et des recherches aupres des universities et des enterprises d’aquitaine - FR
::::* Biocrates Life Sciences AG - Austria
::::* [http://www.biocrates.com/ Biocrates Life Sciences AG] - AT
::::* [http://www.avanticell.com/ AvantiCell Science Ltd] - United Kingdom
::::* [http://www.avanticell.com/ AvantiCell Science Ltd] - UK


[[Image:University_of_Bologna_logo.png‎|50px|University of Bologna]]
[[Image:University_of_Bologna_logo.png‎|50px|University of Bologna]]

Revision as of 15:33, 15 June 2016

                



User talk:Kammerhofer Sylvia/My sandbox

TRANSMIT - TRANSlating the role of MITochondria in Tumorigenesis
Horizon 2020

‎

European commission

Cancer is not only a genetic, but also a metabolic disease

The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer.


Objectives

TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.


Coordinator

Alma Mater Studiorum – Università di Bologna - Italy
Submitted by Anna-Maria Porcelli and Serena Paterlini (University of Bologna)


List of Participants

TRANSMIT is a multi-partner project that intends to mobilize the critical mass of expertise, by linking partners from 7 different countries, among which world-leading basic science and clinical centers of excellence, 4 SMEs as full partners, as well as non-profit foundations with a long-lasting history of dealing with the societal consequences of cancer in patients and their families.


  • Alma Mater Studiorum – UniversitĂ  di Bologna - IT
  • Universite Catholique de Louvain - Belgium
  • OROBOROS INSTRUMENTS GmbH - AT
  • Justus Liebig UniversitĂ€t Giessen - GE
  • GemeinnĂŒtzige Salzburger Landeskliniken Betriebsgesellschaft - AT
  • Karolinska Institutet - Sweden
  • The Chancellor, Masters and Scholars of the University of Cambridge - UK
  • Association pour le dĂ©veloppement de l'enseignement et des recherches aupres des universities et des enterprises d’aquitaine - FR
  • Biocrates Life Sciences AG - AT
  • AvantiCell Science Ltd - UK

University of Bologna Universite Catholique de Louvain link=http://wiki.oroboros.at/index.php/OROBOROS_INSTRUMENTS OROBOROS Justus Liebig UniversitÀt Giessen Salzburger Landeskliniken Karolinska Institutet Adera Biocrates Life Sciences AG AvantiCell Science Ltd University of Cambridge


Partner organisations

  • Fondazione Umberto Veronesi - Italy
  • INNOVA SRL - Italy
  • CEUB.SOC.CONS.ARL - Italy
  • Dynamo Academy srl Impresa Sociale – Italy